Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone Acetate (Zytiga) in Clinical Practice

Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer

“…Several preliminary studies [9][10][11][12][13] have shown aBSI assessment to be a prognostic biomarker for mCRPC. However, the scope of all previous studies in demonstrating the clinical utility of the aBSI as a prognostic biomarker has been limited because of the nature of retrospective ad hoc analyses.…”

Role of bone scan index in the prognosis and effects of therapy on prostate cancer with bone metastasis: Study design and rationale for the multicenter Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index (PROSTAT‐BSI) study

“…The advent of new drugs, such as abiraterone, enzalutamide and cabazitaxel, might increase the possibility of improving bone metastasis. 16 Internal radiation therapy with the alpha-emitter radium-223 is now available in Japan. 23 Although these novel therapeutic possibilities are not included in the present study, methodological advances in using BSI to monitor the treatment of bone metastasis could enhance its future application as a bone biomarker in patients with prostate cancer, and finally contribute to additional treatments that could prolong survival.…”

“…[5][6][7] This software is called BONENAVI (FUJIFILM RI Pharma, Tokyo, Japan) in Japan, and was revised from the original EXINI bone software (EXINI Diagnostics, Lund, Sweden) in a multicenter project involving a large Japanese database. 16 However, few prospective multicenter studies have examined the value of the BSI. 10 Several prior studies have shown that computer-assisted analysis improves classification and is thus applicable to diagnostics.…”

“…5,[11][12][13] Its value has also been investigated in patients with prostate cancer for prognostic purposes, 6,14,15 and the BSI has proven useful for determining the effects of androgen deprivation and chemotherapy. 16 However, few prospective multicenter studies have examined the value of the BSI. A multicenter registry (PROSTAT-BSI) comprising data derived from patients who have prostate cancer with bone metastasis in Japan has been established.…”

Automated Bone Scan Index as an Imaging Biomarker to Predict Overall Survival in the Zometa European Study/SPCG11

“…The value of the aBSI analysis has been demonstrated for prognostication in PCa patients before androgen deprivation therapy [4]. It has also been shown to be a potential tool for monitoring response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel, new androgen signalling inhibitors, or tasquinimod [8][9][10][11][12]. Results from these studies have shown a strong correlation between aBSI and overall survival (OS), with a cut-off value of 1% of metastatic burden [4,13].…”